MEDP - NASDAQ

Medpace Holdings, Inc.

MEDP·NASDAQ

$450.81

+1.2%

HealthcareMedical - Diagnostics & Research

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$12.88B

EPS15.6400

P/E Ratio28.82

Earnings Date07/20/2026

1.98B

Assets

-6%

3Y+46.0%

5Y+42.0%

10Y+102.0%

1.52B

Total Liabilities

19%

3Y+57.0%

5Y+159.0%

10Y+312.0%

459.07M

Total Equity

-44%

3Y+19.0%

5Y-43.0%

10Y-25.0%

Medpace Holdings, Inc. Funding & Solvency Profile

MEDP · NASDAQ

Current Assets

Cash & Cash Equivalents497.05M

Net Receivables402.08M

Inventory0.00

Other Current Assets90.50M

Total Current Assets990 M

Non-Current Assets

Property, Plant & Equipment248.87M

Goodwill & Intangible Assets695.82M

Long-Term Investments0.00

Other Non-Current Assets21.94M

Total Non-Current Assets271 M

Total Assets

1.98B

Financial Health Analysis

Current Ratio

0.74x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Debt-to-Equity Ratio

3.30x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

-354124000

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

50% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Financial stress indicators: Both liquidity and leverage metrics raise concerns. The company may face challenges meeting obligations and should focus on strengthening its balance sheet.

Medpace Holdings, Inc. Balance Sheet

MEDP • NASDAQ

Medpace Holdings, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	497M	669.4M	245.4M	28.3M	461.3M	277.8M	131.9M	23.3M	26.5M	37.1M	14.9M	54.3M
Cash & Short-Term Investments	497M	669.4M	245.4M	28.3M	461.3M	277.8M	131.9M	23.3M	26.5M	37.1M	14.9M	54.3M
Net Receivables	402.1M	296.4M	298.4M	253.4M	186.4M	161M	155.7M	133.4M	83.1M	79.8M	65.1M	65.2M
Accounts Receivables	402.1M	291.1M	275.9M	213M	150.3M	137.9M	155.7M	133.4M	83.1M	79.8M	40.7M	52.5M
Other Receivables	0.0	5.3M	22.5M	40.4M	36.1M	23.4M	0.0	0.0	0.0	0.0	26.1M	12.8M
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7K	7K	308K	2.9M	1.1M
Prepaids	0.0	0.0	0.0	0.0	43.2M	34.9M	29.4M	21.4M	20.4M	16.1M	11.3M	11.2M
Other Current Assets	90.5M	63.4M	50M	52.3M	0.0	0.0	0.0	7K	7K	308K	2.9M	1.1M
Total Current Assets	989.6M	1B	593.8M	334M	690.9M	473.7M	317M	178.1M	130M	133.2M	94.7M	133.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	248.9M	252.3M	265.4M	248.9M	222.7M	198.8M	99.4M	52.3M	48.7M	43.8M	37.5M	38.1M
Goodwill	662.4M	662.4M	662.4M	662.4M	662.4M	662.4M	662.4M	661M	661M	661M	661M	670.3M
Intangible Assets	33.4M	34.4M	35.8M	38M	41.4M	46.5M	54.4M	69.2M	98.7M	136.1M	186.7M	249.9M
Goodwill & Intangible Assets	695.8M	696.8M	698.2M	700.4M	703.8M	708.9M	716.7M	730.2M	759.7M	797.1M	847.7M	920.2M
Tax Assets	19.2M	100.4M	74.4M	48.1M	25.1M	536K	376K	713K	6.3M	97K	157K	138K
Other Non-Current Assets	21.9M	22.3M	25M	21.1M	17.4M	8.8M	9.5M	6.7M	5.9M	4.9M	3.9M	5.2M
Total Non-Current Assets	985.8M	1.1B	1.1B	1B	969M	917M	826M	789.8M	820.7M	845.9M	889.3M	963.6M
Total Assets	2B	2.1B	1.7B	1.4B	1.7B	1.4B	1.1B	967.9M	950.7M	979.1M	984M	1.1B
LIABILITIES
CURRENT LIABILITIES
Total Payables	28.1M	32.5M	31.9M	33.1M	25.7M	26.6M	22.4M	16.7M	16.7M	10.9M	8.7M	6.3M
Accounts Payable	28.1M	32.5M	31.9M	33.1M	25.7M	26.6M	22.4M	16.7M	16.7M	10.9M	8.7M	6.3M
Accrued Expenses	80.1M	222.9M	217.1M	138.9M	101.4M	94.2M	75.1M	56.1M	4M	3M	2.9M	2.1M
Short Term Debt	23.2M	23.3M	0.0	50M	0.0	0.0	0.0	0.0	16.5M	12.4M	59K	0.0
Deferred Revenue	854.4M	710.6M	559.9M	462.7M	344.6M	255.7M	192.4M	147.9M	73.8M	65.7M	51.1M	58.1M
Other Current Liabilities	357.9M	115.3M	116.3M	118.7M	85.5M	63.7M	53.1M	36.2M	81.8M	76.7M	71.3M	67.2M
Total Current Liabilities	1.3B	1.1B	925.1M	803.5M	557.2M	440.1M	343M	257M	192.7M	168.6M	134M	133.6M
NON-CURRENT LIABILITIES
Long Term Debt	113.6M	0.0	0.0	0.0	0.0	0.0	0.0	79.7M	205.1M	151.3M	377.9M	491.5M
Deferred Tax Liabilities (Non-Current)	9.7M	1.8M	2.4M	1.1M	1.1M	13.6M	12.8M	439K	560K	12M	21.1M	33.8M
Other Non-Current Liabilities	-64.3M	42.7M	28.2M	22.7M	17.7M	16.1M	15.7M	41M	48.8M	36.5M	37.6M	36M
Total Non-Current Liabilities	172.7M	170.8M	172.7M	162.6M	149.8M	144.8M	73.8M	121.2M	254.5M	199.8M	436.6M	561.3M
Capital Lease Obligations	113.6M	126.2M	142.1M	138.9M	131M	115.1M	45.2M	24.5M	26.6M	28.5M	30.3M	31.9M
Total Liabilities	1.5B	1.3B	1.1B	966.1M	707M	584.9M	416.8M	378.2M	447.2M	368.4M	570.6M	694.9M
SHAREHOLDERS' EQUITY
Treasury Stock	-12.2M	-12.2M	-12.3M	-12.5M	-5.4M	-5.6M	-6M	-6M	-6M	0.0	0.0	0.0
Common Stock	284K	306K	308K	309K	360K	355K	360K	356K	355K	407K	326K	313K
Additional Paid-In Capital	935.8M	844.1M	802.7M	770.8M	727.9M	695.9M	666.6M	639.4M	630.3M	623.6M	438.7M	417.6M
Retained Earnings	-460M	8.2M	-221.6M	-359.8M	235M	115.2M	68.1M	-41.5M	-120.4M	-9.6M	-23M	-14.3M
Accumulated Other Comprehensive Income/Loss	-4.9M	-14.7M	-10.1M	-12.4M	-4.8M	-131K	-2.7M	-2.5M	-734K	-3.7M	-2.6M	-1.6M
Total Stockholders' Equity	459.1M	825.5M	559M	386.4M	952.9M	805.8M	726.3M	589.7M	503.5M	610.7M	413.5M	402M
Total Equity	459.1M	825.5M	559M	386.4M	952.9M	805.8M	726.3M	589.7M	503.5M	610.7M	413.5M	402M
SUMMARY
Total Liabilities & Equity	2B	2.1B	1.7B	1.4B	1.7B	1.4B	1.1B	967.9M	950.7M	979.1M	984M	1.1B
Total Debt	250.5M	149.5M	142.1M	188.9M	131M	115.1M	45.2M	79.7M	221.6M	163.6M	377.9M	491.5M
Net Debt	-246.6M	-519.9M	-103.3M	160.6M	-330.3M	-162.6M	-86.7M	56.4M	195.1M	126.5M	363.1M	437.2M
Shares Outstanding	28,168,223	28,168,223	28,168,223	28,168,223	28,168,223	28,168,223	28,168,223	28,168,223	28,168,223	28,168,223	28,168,223	28,168,223

SEC Filings

MEDP - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 19, 2026	May 15, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 23, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 22, 2026	April 21, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 01, 2026	May 15, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 10, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 09, 2026	February 09, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	October 23, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 22, 2025	October 22, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	July 22, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 21, 2025	July 17, 2025	2025	View Filing

Showing 1 to 10 of 142 filings

Related Guides

Blog Categories

Continue your MEDP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.